Orion Infusions (DHA:ORIONINFU) Interest Expense: BDT-35.7 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONINFU Orion Infusions Ltd DHA:ORIONINFU
81 GF Score
Price BDT291.20
GF Value BDT316.17
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Orion Infusions Interest Expense?

Orion Infusions DHA:ORIONINFU +0.10% 81 Interest Expense is BDT-35.7 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 81/100 and a GF Value™ of BDT316.17 (Fairly Valued). The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Orion Infusions's interest expense for the three months ended in Mar. 2026 was BDT -0.2 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-35.7 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Orion Infusions's Operating Income for the three months ended in Mar. 2026 was BDT 7.4 Mil. Orion Infusions's Interest Expense for the three months ended in Mar. 2026 was BDT -0.2 Mil. Orion Infusions's Interest Coverage for the quarter that ended in Mar. 2026 was 36.78. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Orion Infusions  (DHA:ORIONINFU) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Orion Infusions's Interest Expense for the three months ended in Mar. 2026 was BDT-0.2 Mil. Its Operating Income for the three months ended in Mar. 2026 was BDT7.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was BDT11.0 Mil.

Orion Infusions's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*7.392/-0.201
=36.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Orion Infusions Interest Expense Historical Data

* Premium members only.

The historical data trend for Orion Infusions's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Infusions Interest Expense Chart

Orion Infusions Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.82 -29.45 -29.51 -34.06 -41.16

Orion Infusions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.82 -13.94 -7.53 -14.00 -0.20
DHA:ORIONINFU
81GF Score
Orion Infusions Ltd DHA:ORIONINFU
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Infusions Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-35.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of BDT-35.7 Mil mean?
Orion Infusions (DHA:ORIONINFU) has a Interest Expense of BDT-35.7 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Orion Infusions and its competitors.
Is Orion Infusions' Interest Expense too high?
Orion Infusions' current Interest Expense is BDT-35.7 Mil. Overall, Orion Infusions has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Interest Expense compare to ZTS and UTHR?
Orion Infusions' Interest Expense of BDT-35.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Orion Infusions and its competitors. Orion Infusions's current Interest Expense is BDT-35.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Fairly Valued. The stock's GF Value™ is BDT316.17, compared to a current price of BDT291.20 — trading 7.9% below its estimated fair value. The current Interest Expense is BDT-35.7 Mil. Orion Infusions' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Interest Expense is BDT-35.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued. The current stock price of BDT291.20 is trading 7.9% below its estimated GF Value™ of BDT316.17. GuruFocus considers Orion Infusions to be Fairly Valued.

Key valuation signals for DHA:ORIONINFU:

  • Interest Expense: BDT-35.7 Mil
  • GF Value™: BDT316.17 vs. price of BDT291.20 (7.9% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Infusions Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
81GF Score

Get the complete analysis for DHA:ORIONINFU

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT291.20
Price
BDT316.17
GF Value